Skip to main content

Applying high throughput DNA encoded library (DEL) drug screening combined with other advanced technologies in novel ways to deliver therapeutics that address some of the most challenging targets in clinical medicine, some that in the past have even been called “undruggable”



Targeting Kinases

While there are more than 500 kinases encoded within the human genome with over 70 FDA approved small molecule kinase inhibitors, mostly for cancer indications, resistance to first line inhibitors often leads to cancer recurrence and poor prognosis. The development of new drugs that overcome such cancer resistance is still a critical unmet medical need.

Targeting Nuclear Receptors

Nuclear receptors can bind ligand, leading to a conformational change, homo- or hetero-dimerization, nuclear translocation and DNA binding.

Driving Apoptosis of Senolytic Cells

DNA damage, oxidative stress or oncogenic mutations can activate nuclear translocation of p53 and p53 interacting proteins (p53IP), helping to tether p53 onto the transcriptional promoter of pro-senescence protein, p21.

Deliver Graphic


Our early pipeline is focused on identifying novel drug candidates, both small molecules or peptides, that target nuclear receptors, senolytics and tyrosine kinases.



December 14, 2021 in Press Releases

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

DELIVER Therapeutics, Inc. ("DELIVER") a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible…
Read More
November 15, 2021 in News

New use of screening technology finds SARS-CoV-2 treatment target in lab setting

Finding effective treatments for SARS-CoV-2, the viral agent responsible for COVID-19, has been difficult but researchers at Baylor College of Medicine are working to find a potential solution. Much attention…
Read More